News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
252,062 Results
Type
Article (6416)
Company Profile (24)
Press Release (245622)
Multimedia
Podcasts (2)
Webinars (4)
Section
Business (87510)
Career Advice (468)
Deals (16413)
Drug Delivery (8)
Drug Development (21461)
Employer Resources (30)
FDA (4349)
Job Trends (4315)
News (130445)
Policy (8664)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (308)
Accelerated approval (6)
Adcomms (4)
Allergies (14)
Alliances (16508)
ALS (38)
Alzheimer's disease (315)
Antibody-drug conjugate (ADC) (47)
Approvals (4467)
Artificial intelligence (85)
Autoimmune disease (28)
Automation (5)
Bankruptcy (104)
Best Places to Work (3054)
Biosimilars (33)
Biotechnology (23)
Bladder cancer (34)
Brain cancer (8)
Breast cancer (105)
Cancer (950)
Cardiovascular disease (69)
Career advice (399)
Career pathing (3)
CAR-T (64)
CDC (2)
Cell therapy (167)
Cervical cancer (5)
Clinical research (18846)
Collaboration (382)
Compensation (387)
Complete response letters (8)
COVID-19 (334)
CRISPR (13)
C-suite (362)
Cystic fibrosis (29)
Data (1448)
Denatured (1)
Depression (29)
Diabetes (105)
Diagnostics (2215)
Digital health (9)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (33)
Drug pricing (14)
Drug shortages (2)
Duchenne muscular dystrophy (37)
Earnings (44720)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (41236)
Executive appointments (448)
FDA (5152)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (362)
Gene editing (24)
Generative AI (7)
Gene therapy (107)
GLP-1 (154)
Government (462)
Guidances (205)
Healthcare (5252)
HIV (19)
Huntington's disease (5)
IgA nephropathy (11)
Immunology and inflammation (40)
Immuno-oncology (8)
Indications (21)
Infectious disease (365)
Inflammatory bowel disease (37)
Inflation Reduction Act (3)
Influenza (7)
Intellectual property (35)
Interviews (53)
IPO (8208)
IRA (3)
Job creations (1345)
Job search strategy (365)
JPM (4)
Kidney cancer (10)
Labor market (10)
Layoffs (110)
Leadership (5)
Legal (2735)
Liver cancer (22)
Longevity (2)
Lung cancer (104)
Lymphoma (71)
Machine learning (3)
Management (10)
Manufacturing (153)
MASH (52)
Medical device (4164)
Medtech (4176)
Mergers & acquisitions (8633)
Metabolic disorders (250)
Multiple sclerosis (19)
NASH (6)
Neurodegenerative disease (58)
Neuropsychiatric disorders (17)
Neuroscience (587)
NextGen: Class of 2026 (1726)
Non-profit (747)
Now hiring (6)
Obesity (91)
Opinion (33)
Ovarian cancer (29)
Pain (26)
Pancreatic cancer (39)
Parkinson's disease (58)
Partnered (6)
Patents (59)
Patient recruitment (105)
Peanut (6)
People (26741)
Pharmaceutical (7)
Pharmacy benefit managers (2)
Phase 1 (5481)
Phase 2 (8012)
Phase 3 (6706)
Pipeline (2081)
Policy (18)
Postmarket research (835)
Preclinical (2092)
Press Release (66)
Prostate cancer (59)
Psychedelics (3)
Radiopharmaceuticals (113)
Rare diseases (187)
Real estate (2024)
Recruiting (8)
Regulatory (6328)
Reports (18)
Research institute (335)
Resumes & cover letters (69)
Rett syndrome (19)
RNA editing (1)
RSV (6)
Schizophrenia (52)
Series A (56)
Series B (58)
Sickle cell disease (10)
Special edition (1)
Spinal muscular atrophy (35)
Sponsored (5)
Startups (1108)
Stomach cancer (1)
Supply chain (15)
Tariffs (7)
The Weekly (1)
Vaccines (93)
Venture capital (10)
Weight loss (30)
Women's health (6)
Date
Today (37)
Last 7 days (174)
Last 30 days (591)
Last 365 days (9405)
2026 (875)
2025 (9540)
2024 (11680)
2023 (13937)
2022 (20390)
2021 (21248)
2020 (19730)
2019 (14246)
2018 (11010)
2017 (11221)
2016 (10364)
2015 (13650)
2014 (10701)
2013 (8450)
2012 (9078)
2011 (9476)
2010 (9337)
Location
Africa (195)
Alabama (20)
Alaska (2)
Arizona (74)
Arkansas (2)
Asia (12435)
Australia (1780)
California (3630)
Canada (1158)
China (172)
Colorado (146)
Connecticut (163)
Delaware (73)
Europe (36991)
Florida (555)
Georgia (67)
Idaho (24)
Illinois (171)
India (21)
Indiana (109)
Iowa (10)
Japan (169)
Kansas (37)
Kentucky (17)
Louisiana (8)
Maine (51)
Maryland (377)
Massachusetts (2949)
Michigan (104)
Minnesota (204)
Mississippi (1)
Missouri (35)
Montana (17)
Nebraska (13)
Nevada (47)
New Hampshire (16)
New Jersey (1038)
New Mexico (5)
New York (855)
North Carolina (517)
North Dakota (4)
Northern California (1895)
Ohio (119)
Oklahoma (5)
Oregon (7)
Pennsylvania (664)
Puerto Rico (2)
Rhode Island (19)
South America (304)
South Carolina (17)
Southern California (1349)
Tennessee (62)
Texas (491)
United States (12823)
Utah (113)
Virginia (115)
Washington D.C. (17)
Washington State (303)
West Virginia (2)
Wisconsin (58)
Wyoming (1)
252,062 Results for "prothena corporation plc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s
Prothena’s Alzheimer’s Drug Comes With Familiar Side Effect in Phase I Test
In another blow to Prothena’s neurodegenerative disease portfolio, anti-amyloid candidate PRX012 has run into the same problem that larger peers Biogen and Eli Lilly have battled: high rates of swelling in the brain.
August 28, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Prothena Announces Board of Directors Update - December 12, 2025
December 15, 2025
·
2 min read
Press Releases
Prothena to Report Third Quarter 2025 Financial Results on November 6
October 31, 2025
·
1 min read
Parkinson’s disease
Roche, Prothena Push Parkinson’s Drug to Phase III Despite Mid-Stage Fail
Analysts at Jefferies give Roche and Prothena’s Phase III study just a 25% to 40% probability of success.
June 16, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
November 20, 2025
·
4 min read
Press Releases
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
November 6, 2025
·
14 min read
Press Releases
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
November 11, 2025
·
4 min read
Rare diseases
Prothena Looks at Business Options as Phase III AL Amyloidosis Trial Fails
Prothena has already discontinued the development of birtamimab, and anticipates further spending cuts, including workforce reduction.
May 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
August 29, 2025
·
1 min read
Press Releases
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
October 2, 2025
·
5 min read
1 of 25,207
Next
